Literature DB >> 11354319

Palliative treatment in patients with unresectable hilar cholangiocarcinoma: results of endoscopic drainage in patients with type III and IV hilar cholangiocarcinoma.

M F Gerhards1, D den Hartog, E A Rauws, T M van Gulik, D González González, J S Lameris, L T de Wit, D J Gouma.   

Abstract

OBJECTIVE: To find out how patients fared after palliative endoscopic biliary drainage for inoperable hilar cholangiocarcinoma.
DESIGN: Retrospective study.
SETTING: University hospital, the Netherlands.
SUBJECTS: Between 1992 and 1999, 41 patients who were referred for resection had tumours that were considered unresectable after additional investigations, including an exploratory laparotomy in 16 patients. In all patients, biliary drainage was established by endoscopic retrograde cholangiography (ERCP) and insertion of endoprostheses. Twelve patients also had percutaneous transhepatic biliary drainage (PTBD).
RESULTS: The patients who did not have an exploratory laparotomy had fewer complications (1/25) than those who had explorations (4/16). All patients in both groups had one or more long-term complications during follow-up, of which cholangitis, jaundice, and abdominal pain were the most often recorded. In 32 patients, endoprostheses had to be replaced, a mean of 4 times. Median survival was 9 months, with no significant difference between the groups (8 and 11 months). Adjuvant radiotherapy had no influence on survival.
CONCLUSION: The patients in this series had relatively long survival times, during which they had a substantial number of complications predominantly related to biliary drainage. Because biliary-enteric bypass operations result in effective relief of symptoms and excellent palliation, we suggest that when an exploration is done for patients with type III and IV tumours, a bypass should be made.

Entities:  

Mesh:

Year:  2001        PMID: 11354319     DOI: 10.1080/110241501300091444

Source DB:  PubMed          Journal:  Eur J Surg        ISSN: 1102-4151


  9 in total

Review 1.  Perihilar cholangiocarcinoma: a surgeon's viewpoint on current topics.

Authors:  Masato Nagino
Journal:  J Gastroenterol       Date:  2012-07-31       Impact factor: 7.527

Review 2.  Photodynamic therapy for unresectable cholangiocarcinoma.

Authors:  Yutaka Tomizawa; Jianmin Tian
Journal:  Dig Dis Sci       Date:  2011-11-06       Impact factor: 3.199

Review 3.  Diagnostic and surgical approaches in hilar cholangiocarcinoma.

Authors:  Gerd Otto
Journal:  Int J Colorectal Dis       Date:  2006-03-31       Impact factor: 2.571

4.  Photodynamic therapy is associated with an improvement in survival in patients with irresectable hilar cholangiocarcinoma.

Authors:  Aaron J Quyn; Dorin Ziyaie; Francesco M Polignano; Iain S Tait
Journal:  HPB (Oxford)       Date:  2009-11       Impact factor: 3.647

5.  Optimal biliary drainage for inoperable Klatskin's tumor based on Bismuth type.

Authors:  Sang Hyub Lee; Joo Kyung Park; Won Jae Yoon; Jun Kyu Lee; Ji Kon Ryu; Yong Bum Yoon; Yong-Tae Kim
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

Review 6.  Hilar cholangiocarcinoma: diagnosis, treatment options, and management.

Authors:  Kevin C Soares; Ihab Kamel; David P Cosgrove; Joseph M Herman; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2014-02       Impact factor: 7.293

7.  Cholangiocarcinoma of the Hepatic Hilum (Klatskin Tumor).

Authors:  Valerie Byrnes; Nezam Afdhal
Journal:  Curr Treat Options Gastroenterol       Date:  2002-04

8.  Evaluation of the effectiveness of endoscopic retrograde cholangiopancreatography in patients with perihilar cholangiocarcinoma and its effect on development of cholangitis.

Authors:  Serkan Ipek; Emrah Alper; Cem Cekic; Serkan Cerrah; Mahmut Arabul; Fatih Aslan; Belkis Unsal
Journal:  Gastroenterol Res Pract       Date:  2014-05-27       Impact factor: 2.260

Review 9.  Endoscopic drainage in patients with inoperable hilar cholangiocarcinoma.

Authors:  Ye Jin Park; Dae Hwan Kang
Journal:  Korean J Intern Med       Date:  2012-12-28       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.